Type 2 diabetes in adolescents: Which treatment?;Diabète de type 2 à l'adolescence: Quels traitements?

Archives de Pediatrie

Volumn 10, Issue SUPPL. 1, 2003, Pages

  Polak, M ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

ADOLESCENT; CONFERENCE PAPER; EXERCISE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; TREATMENT PLANNING;

ADOLESCENT; ALPHA-GLUCOSIDASES; CHILD; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE;

EID: 0038199706     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Ortega-Rodriguez E, Levy-Marchal C, Tubiana N, Czernichow P, Polak M. Emergence of type 2 diabetes in an hospital based cohort of children with diabetes mellitus. Diabetes Metab 2001;27:574-8.
2. Rosenbloom AL, Joe JR, Young RS, Winter WE. The emerging epidemic of type 2 diabetes mellitus in youth. Diabetes Care 1999;22:345-54.
3. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care 2000;23:381-9.
4. Dean H. Treatment of type 2 diabetes in youth: an argument for randomized controlled studies. Paediatr Child Health 1999;4:265-9.
5. Amiel SA, Sherwin RS, Simonson DC, Lauritano AA, Tamborlane WV. Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. N Engl J Med 1986;315:215-9.
6. Arslanian SA. Insulin secretion and sensitivity in healthy African-American vs. American white children. Clin Pediatr 1998;37:81-8.
7. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787-94.
8. Scheen AJ, Charbonnel B. Effets antidiabétiques des thiazolidinediones. Med Ther Endocrinol 2001;3:41-8.
9. De Fonzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995;333:541-9.
10. Lebovitz HE. Insulin secretagogues, old and new. Diabetes Rev 1999;7:139-52.
11. Prospective Diabetes Study UK, Group UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet 1998;352:837-53.
12. Fagot-Campagna A, Knowler WC, Pettitt DJ. Type 2 diabetes in Pima Indian children: cardiovascular risk factors at diagnosis and 10 years later. Diabetes 1998;47:A155.
13. Jones K, Arslanian S, Peterokova VA, Park JS, Tomlinson M. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002;25:89-94.
14. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
15. Hu FB, Manson JE, Stampfer MJ, Colitz G, Liu S, Solomon CG, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med 2001;345:790-7.
16. Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001;107:1-7.